Oral PCSK9 Inhibitor Enlicitide Produces ~58% LDL‑C Reduction in Heterozygous Familial Hypercholesterolemia: A Phase 3 Randomized Trial
Highlights
– Enlicitide decanoate, an oral PCSK9 inhibitor, produced a mean 58.2% reduction in LDL‑C at 24 weeks versus placebo in adults with heterozygous familial hypercholesterolemia (HeFH) on background statin therapy.
– Reductions were durable to 52 weeks (≈55% reduction), and non‑HDL‑C, apolipoprotein B, and lipoprotein(a) also fell significantly.
MedXY registered readers
Sign in free to continue reading
Create or use your MedXY account to unlock the complete article.
This article was created using several editorial tools, including AI, as part of the process. Human editors reviewed this content before publication.